


PHARMACEUTICAL 2020

AYTU BIOPHARMA INC Rank 254 of 362







PHARMACEUTICAL 2020





The relative strengths and weaknesses of AYTU BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AYTU BIOPHARMA INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 176% points. The greatest weakness of AYTU BIOPHARMA INC is the variable Other Net Income, reducing the Economic Capital Ratio by 132% points.

The company's Economic Capital Ratio, given in the ranking table, is -328%, being 25% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	15,433
Cost of Goods Sold	2,202
Intangible Assets	221
Liabilities, Current	5,373
Liabilities, Non-Current	0
Other Assets	18,864
Other Compr. Net Income	0
Other Expenses	2,488
Other Liabilities	22,261
Other Net Income	-10,285
Property and Equipment	204
Research and Development	589
Revenues	7,320
Selling, General and Administrative Expense	18,888

Output Variable	Value in 1000 USD
Assets	34,721
Liabilities	27,634
Expenses	24,167
Stockholders Equity	7,088
Net Income	-27,132
Comprehensive Net Income	-27,132
Economic Capital Ratio	-328%